<p><h1>Zoster Vaccine Live Market Size, Market Share and Global Market Analysis Report, 2024 - 2031</h1></p><p><strong>Zoster Vaccine Live Market Analysis and Latest Trends</strong></p>
<p><p>Zoster Vaccine Live, commonly known as the shingles vaccine, is a medication used to prevent shingles (herpes zoster). It is a live attenuated vaccine that contains a weakened form of the varicella-zoster virus, which also causes chickenpox. The vaccine works by stimulating the immune system to produce antibodies against the virus, providing protection against shingles.</p><p>The Zoster Vaccine Live Market has witnessed significant growth in recent years and is expected to continue growing at a CAGR of 8.1% during the forecast period. The increasing geriatric population, rising prevalence of shingles, and growing awareness about the vaccine and its benefits are the major factors contributing to the market growth. Moreover, the introduction of government initiatives and immunization programs for shingles prevention is further fuelling the demand for the vaccine.</p><p>Furthermore, advancements in vaccine manufacturing techniques and innovative delivery systems are expected to drive market growth. For instance, the development of a new adjuvanted subunit vaccine for shingles prevention shows promising results in clinical trials. This vaccine is expected to offer improved efficacy and long-term protection compared to the existing live attenuated vaccine.</p><p>In terms of regional analysis, North America is expected to dominate the Zoster Vaccine Live Market due to the high incidence rate of shingles and the presence of a well-established healthcare infrastructure. Additionally, the Asia-Pacific region is anticipated to witness significant growth in the market, primarily due to the increasing geriatric population and rising healthcare expenditure in countries like China and India.</p><p>Overall, the Zoster Vaccine Live Market is poised to grow substantially in the coming years, driven by factors such as the aging population, rising prevalence of shingles, and advancements in vaccine technology.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1669353">https://www.reliableresearchreports.com/enquiry/request-sample/1669353</a></p>
<p>&nbsp;</p>
<p><strong>Zoster Vaccine Live Major Market Players</strong></p>
<p><p>The global zoster vaccine live market is highly competitive, with key players including Merck and GlaxoSmithKline (GSK). These companies have established themselves as major players in the market and continue to drive growth through product innovations, strategic partnerships, and strong market presence.</p><p>Merck, a multinational pharmaceutical company, offers the Zostavax vaccine. Zostavax is an FDA-approved vaccine indicated for the prevention of shingles in adults aged 50 years and older. The company has witnessed significant market growth due to the increasing prevalence of shingles and the growing geriatric population worldwide. Merck's strong market presence and extensive distribution network have contributed to its success, propelling its market growth.</p><p>GSK, another leading pharmaceutical company, offers the Shingrix vaccine. Shingrix is also approved by the FDA and is recognized as a highly effective vaccine against shingles. GSK has experienced remarkable market growth with the launch of Shingrix, primarily because of its higher efficacy compared to its competitors. The company has tapped into the increasing demand for effective and durable vaccines and has established a strong market position.</p><p>The global zoster vaccine live market is expected to witness substantial growth in the coming years. The growing geriatric population, rising awareness about vaccination, and the introduction of advanced vaccines are the key factors driving market growth. Moreover, the prevalence of shingles is expected to increase, further boosting the demand for zoster vaccines. The global market size for zoster vaccine live is projected to reach billions of dollars by the end of the forecast period.</p><p>In terms of revenue, Merck reported annual sales of approximately $47.4 billion in 2020. The revenue generated from the sales of Zostavax was not specifically disclosed in the company's financial reports. On the other hand, GSK reported annual sales of approximately $43.8 billion in 2020, with Shingrix contributing significantly to the company's vaccine portfolio revenue. Specific revenue figures for Shingrix were not disclosed separately.</p><p>Overall, both Merck and GSK are key players in the global zoster vaccine live market, with strong market growth prospects in the foreseeable future. These companies continue to focus on research and development activities to introduce advanced vaccines to further expand their market share. The market for zoster vaccine live is poised for significant growth, driven by increasing prevalence rates and the rising adoption of vaccination as a preventive measure.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Zoster Vaccine Live Manufacturers?</strong></p>
<p><p>The Zoster Vaccine Live market is expected to witness significant growth in the coming years. This is primarily due to the increasing prevalence of shingles and postherpetic neuralgia, which can be prevented by this vaccine. Additionally, the growing geriatric population and increasing awareness regarding vaccination are driving market growth. Furthermore, advancements in technology and the development of targeted therapies are expected to fuel market expansion. However, limited access to healthcare in certain regions and high costs associated with the vaccine may hinder market growth. Overall, the Zoster Vaccine Live market is projected to experience a positive outlook in the foreseeable future.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1669353">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1669353</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Zoster Vaccine Live Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Monovalent Vaccine</li><li>Combination Vaccine</li></ul></p>
<p><p>The Zoster Vaccine Live market is divided into two types: monovalent vaccine and combination vaccine. </p><p>Monovalent vaccines target a specific strain or type of the varicella-zoster virus, providing protection against that specific strain. On the other hand, combination vaccines offer protection against multiple strains or types of the virus in a single dose. </p><p>Both market types aim to prevent shingles, a painful rash caused by the varicella-zoster virus, by stimulating the immune system to recognize and fight the virus. These vaccines are important in reducing the risk of shingles and its associated complications among individuals, particularly those at high risk.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1669353">https://www.reliableresearchreports.com/purchase/1669353</a></p>
<p>&nbsp;</p>
<p><strong>The Zoster Vaccine Live Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Kids Injection</li><li>Adults Injection</li></ul></p>
<p><p>The Zoster Vaccine Live is used to prevent herpes zoster (shingles) in children and adults. In the kids' injection market, it is administered to children to protect them against shingles and its complications. In the adults' injection market, it is given to adults to lower the risk of developing shingles and alleviate the severity if they get infected. By providing immunity against the varicella-zoster virus, this vaccine addresses the needs of both age groups in preventing shingles infection.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Zoster Vaccine Live Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Zoster Vaccine Live market is expected to witness significant growth across various regions including North America (NA), Asia-Pacific (APAC), Europe, the United States (USA), and China. The North American market is anticipated to dominate the global market, accounting for the largest market share percentage valuation. This can be attributed to the increasing aging population and rising occurrences of herpes zoster in the region. Additionally, robust healthcare infrastructure and favorable government initiatives further drive the market growth. The APAC region is also projected to experience substantial growth, primarily due to the expansion of the healthcare sector and the presence of a large geriatric population.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1669353">https://www.reliableresearchreports.com/purchase/1669353</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1669353">https://www.reliableresearchreports.com/enquiry/request-sample/1669353</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>